美国食品药品监督管理局（FDA）已正式受理渤健公司旗下Leqembi®（Lecanemab-Irmb）的补充生物制剂许可申请，将其皮下注射起始剂量方案纳入优先审评通道，用于治疗早期阿尔茨海默病。此次审评聚焦于该疗法在给药方式上的创新突破，有望为患者提供更便捷的治疗选择。
美国食品药品监督管理局（FDA）已正式受理渤健公司旗下Leqembi®（Lecanemab-Irmb）的补充生物制剂许可申请，将其皮下注射起始剂量方案纳入优先审评通道，用于治疗早期阿尔茨海默病。此次审评聚焦于该疗法在给药方式上的创新突破，有望为患者提供更便捷的治疗选择。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.